
|Videos|July 7, 2020
Expanding Options for Relapsed/Refractory HER2+ Metastatic Breast Cancer
Author(s)Targeted Oncology
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































